FASN and Hypoglycemia: The direct inhibition of FASN might trigger chronic on-target safety risks due to the reduced β-oxidation of fatty acids by compromising the activity of PPARα, since FASKOL mice showed lipid accumulation and hypoglycemia with a zero-fat diet or fasting.